Vyvgart Hytrulo Challenges the Step Therapy Model in Treatment-Naive CIDP
Post hoc ADHERE analysis shows Vyvgart Hytrulo delivers early responses in 87.5% of treatment-naive CIDP patients, challenging step-therapy policies and prompting reconsideration of first-line treatment strategies.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.